Proactive Investors - Run By Investors For Investors

Botanix Pharmaceuticals treats first patient in phase 1b psoriasis study

Uniquely designed patient study which allows the comparison of multiple drugs on the same patient at the same time.
BTX 1308 is Botanix’s third product to commence a patient study in the last 12 months

Botanix Pharmaceuticals Ltd (ASX:BOT) has treated the first patient in its phase 1b BTX 1308 psoriasis patient study.

The study is testing a new formulation of synthetic cannabidiol combined with the company’s novel Permetrex skin delivery technology.

The phase 1b patient study is being conducted in collaboration with BioSkin GmbH, a German clinical contract research organisation and an Australian dermatology clinic.

Bioskin is internationally recognised for their experience with the psoriasis plaque test which is clinically validated and utilised by a number of leading dermatology companies.

The study is designed to assess the safety and efficacy of BTX 1308 on psoriasis plaques or lesions, with the ability to compare multiple formulations and test products at the same time, and on the same patient.

Botanix is advancing multiple clinical programs with near-term milestones

Botanix founder and executive director Matt Callahan said: “We are pleased to have enrolled and treated our first patient in the BTX 1308 psoriasis study.

“The unique design of this patient study which allows us to compare multiple drugs in the same patient at the same time, means that the treatment duration can be shortened, while the quality of data can also be enhanced.

“BTX 1308 is our third product to commence a patient study in the last 12 months, which demonstrates our ability to rapidly add new indications to the pipeline, as we can leverage the studies already successfully completed with synthetic cannabidiol in acne and atopic dermatitis.”

View full BOT profile View Profile

Botanix Pharmaceuticals Ltd Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
December 17 2018
Summit has big plans for its flagship ridinilazole C. Diff treatment as well as its gonorrhoea and hospital superbug candidates this year, and it now has the funds to develop all of them as intended
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use